Injection Semaglutide: The Molecule That Comes Both Ways

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Brought to you by the PlexusDx Education Hub, your reference for GLP-1 formats, weight-management choices, and the genetics that shape them.

Semaglutide is the one GLP-1 molecule most likely to leave people confused about format, because it genuinely exists in two — a weekly injection and a daily pill. Understanding which is which, and what each is approved for, clears up most of the "injection semaglutide" question. Here is how the formats map, how they behave, and where the genetics sit.

The one GLP-1 sold as both a shot and a pill

Semaglutide is available in two formats as of April 2026, which is unusual in this drug class and the source of a lot of mixed-up searches. Knowing that both exist — and that they are approved for different things — is the key to reading any semaglutide comparison correctly.

Mapping semaglutide's two formats

The two sides differ by product, route, and indication.

The injectable side

As a once-weekly subcutaneous injection, semaglutide is sold as Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management), both Novo Nordisk. PlexusDx offers Semaglutide Injection as one protocol.

The oral side

As a once-daily oral tablet, semaglutide is sold as Rybelsus, also Novo Nordisk, labeled for type 2 diabetes. There is no oral semaglutide product FDA-approved for chronic weight management as of April 2026. PlexusDx offers Semaglutide Oral as a separate protocol.

Why delivery method matters

Injectable GLP-1 receptor agonists deliver predictable bioavailability and are typically dosed once weekly (liraglutide, once daily). Oral GLP-1 receptor agonists must survive gastric digestion, so Rybelsus uses an absorption enhancer (SNAC) and requires strict fasting administration. Real-world adherence depends on preference, injection tolerance, timing needs, and lifestyle, and head-to-head efficacy data between the two formats in chronic weight management is limited.

Titration numbers you'll hear

Injectable semaglutide is titrated per label from 0.25 mg weekly through higher doses (Ozempic up to 2 mg, Wegovy up to 2.4 mg). Rybelsus starts at 3 mg daily and titrates to 7 or 14 mg. For context, injectable tirzepatide runs from 2.5 mg weekly up to 15 mg. These label figures never replace your prescriber's directions.

Cost and coverage differ by format

The two formats are priced separately, follow different insurance coverage rules, and may qualify differently for manufacturer savings programs. The PlexusDx Weight Management Protocols publish per-protocol pricing on each relevant product page.

Genetics upstream of your semaglutide plan

Whichever format you and a provider consider, the biology underneath is shared. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights — including variants in FTO, GLP1R, and TCF7L2 that shape appetite regulation, baseline GLP-1 signaling, and energy balance. It never predicts response to semaglutide or any medication; it is trait context, not a forecast. Compare with injectable Ozempic and injectable Wegovy.

Treat this as educational content. Through its Weight Management Protocols, PlexusDx offers semaglutide and tirzepatide and no other GLP-1 compound, including dulaglutide, liraglutide, cagrilintide, and retatrutide. Retatrutide is investigational and is not sold by PlexusDx. The Precision Peptide Genetic Test does not predict your response to any specific medication. Check with a qualified healthcare provider before starting a peptide protocol.

Choosing between the two semaglutide formats

Having both an injection and a tablet available makes the format decision more personal than it is for injection-only molecules. The practical factors are familiar: comfort with weekly injections versus a daily pill, the ability to follow strict fasting rules for the oral tablet, insurance coverage, and the approved indication that fits your situation. It also matters that the oral tablet is labeled for type 2 diabetes, while chronic weight management has no FDA-approved oral semaglutide as of April 2026. Your prescribing provider weighs these considerations alongside your medical history, concurrent medications, and side-effect profile before recommending a format. The two share a molecule, so this is genuinely a delivery decision rather than a choice between different drugs.

Frequently Asked Questions

Is there an oral version of semaglutide?

Yes — Rybelsus is the oral semaglutide tablet, and as of April 2026 it is the only FDA-approved oral GLP-1 receptor agonist. However, it is labeled for type 2 diabetes, not chronic weight management. There is no oral semaglutide FDA-approved for weight management, and there is no FDA-approved oral tirzepatide.

What is the difference between Ozempic and Wegovy?

Both are once-weekly injectable semaglutide from Novo Nordisk, but Ozempic is labeled for type 2 diabetes and Wegovy for chronic weight management, with Wegovy titrated up to 2.4 mg. They share the molecule and route while differing in approved indication and dosing ceiling, which is why the brand names are not interchangeable.

How do the injection and tablet compare?

The injection provides predictable bioavailability with weekly dosing. The Rybelsus tablet relies on an absorption enhancer and strict fasting rules. Head-to-head weight-management efficacy data between the formats is limited, and oral semaglutide is approved for type 2 diabetes rather than weight management, so the right format is an individual decision.

Can genetics tell me which semaglutide format to use?

No. The Precision Peptide Genetic Test does not predict response to any compound or delivery format. It reads pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that relate to baseline GLP-1 and energy-balance biology — upstream context that applies to injection and tablet alike, not a recommendation of one over the other.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.